Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma
Lung Cancer Aug 29, 2019
Morra F, Merolla F, D’Abbiero D, et al. - In this investigation, researchers studied the functional role of CCDC6 (coiled-coil domain containing 6) in Malignant Pleural Mesothelioma (MPM), aggressive cancer with poor prognosis, carcinogenesis and response to PARP-inhibitors. By co-immunoprecipitation, the interaction between CCDC6 and BAP1 was confirmed in MPM cells. According to results, CCDC6-depleted MPM cells had repair and sensitivity defects in DSBs to PARP inhibitors. The staining of CCDC6 and of its de-ubiquitinase USP7 displayed a significant relationship in the tested primary samples in the TMA of MPM primary samples. In 30% of the tumors that also carried BAP1 defects, CCDC6 was scarcely identified. The authors concluded that the combination of CCDC6 and BAP1 staining may show therapeutic possibilities for targeting DDR, acting in cisplatinum synergism.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries